Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...

In patients with type 2 diabetes and cirrhosis, SGLT2 inhibitors show increased efficacy over DPP-4 inhibitors in kidney, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Data derived from: D ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual ...

Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...